drugset

drugset / Trial / NCT00144573

Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment

NCT00144573 ↗

Completed 14 enrolled Chugai Pharmaceutical

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, clinical pharmacology study to evaluate the safety and PK of MRA in patients with RA with Renal Impairment.

Timeline

Start: 2005-01
Primary completion: 2005-10
Completion: 2005-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tocilizumab	Monoclonal antibody	—	—

Indications